Optimizing Ultrasound Enhanced Delivery of Therapeutics
优化超声增强治疗的输送
基本信息
- 批准号:9337418
- 负责人:
- 金额:$ 62.44万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-08-25 至 2021-07-31
- 项目状态:已结题
- 来源:
- 关键词:Academic Medical CentersAcousticsAddressAdjuvantAnimalsBiodistributionBiologicalCancer EtiologyCell LineCessation of lifeClinicClinicalClinical TrialsContrast MediaCustomDataDevelopmentDiagnosticDiseaseDrug Delivery SystemsEastern Cooperative Oncology GroupEffectivenessEnrollmentEnvironmentEquipmentExcisionGoalsHumanImage EnhancementImmunohistochemistryIn VitroIndustrializationInstitutesIsraelLeadLeadershipLiverMalignant neoplasm of pancreasMediatingMedicalMethodologyMethodsMicrobubblesMonitorMulti-Institutional Clinical TrialOperative Surgical ProceduresOrganOutcomePancreasPancreatic AdenocarcinomaPancreatic Ductal AdenocarcinomaPatient-Focused OutcomesPatientsPharmaceutical PreparationsPharmacotherapyPre-Clinical ModelProtocols documentationPublishingRadiationResearchResearch PersonnelSolid NeoplasmSurvival RateSystemSystemic TherapyTechniquesTechnologyTherapeuticTranslatingTumor VolumeUltrasonographyUnited StatesUniversitiesUniversity HospitalsUnresectableWomanX-Ray Computed Tomographybasecancer diagnosischemotherapyclinical investigationclinical practiceclinically translatablecontrast enhanceddesignhuman studyimage-guided drug deliveryimaging modalityimaging platformimprovedimproved outcomeinnovationmenmouse modelmultidisciplinarynew therapeutic targetnovelpre-clinical researchprogramsquantitative imagingquantitative ultrasoundstandard of caretooltreatment response
项目摘要
Abstract
Pancreatic cancer is the third most common cancer diagnosed in the United States, with more than
43,000 new cases in 2013. It is the fourth leading cause of cancer-related death in both men and women.
Nonetheless, there has been no significant improvement in survival for pancreatic ductal adenocarci-
noma (PDAC) patients over the past 30+ years. For this reason, there is a considerable and urgent
clinical need to develop innovative strategies for effective drug delivery and treatment monitoring, re-
sulting in improved outcomes for patients with PDAC. Our proposal aims at developing contrast-enhanced
ultrasound-mediated image-guided drug delivery (CEUS-IGDD) to be that methodology and to translate it from
the lab to the clinic. The specific tasks are designed to improve the understanding and methodology for control
and monitoring of this IGDD platform, with an initial clinical focus on enhancing the effectiveness of standard
chemotherapeutics for treatment of inoperable PDAC.
Inherently this project constitutes a multidisciplinary challenge (technological, biological, physical, and
medical), and our strategy to address the critical barriers therefore unites an interdisciplinary team of academic
and industrial investigators from GE Global Research (GE), Haukeland University Hospital and University of
Bergen (together: Bergen), Thomas Jefferson University (TJU), and Rush University Medical Center with
more limited efforts by the Israel Institute of Technology and GlaxoSmithKline (GSK).
Aim 1 will develop tools and methods to ascertain optimal conditions (acoustic regime, bubble type) for
maximum drug delivery with minimal application of diagnostic-range acoustic energy. Aim 2 utilizes two com-
plementary established pancreatic adenocarcinoma mouse models, using human MIA PaCa-2luc (Bergen) and
PANC-1 (TJU) cell lines. The efficacy of CEUS-IGDD will be evaluated using biodistribution data and quan-
titative imaging methods to monitor treatment response expecting a greater median survival of at least 5
days and a median tumor volume reduction of 50% in the treated group compared to animals receiving
drug alone. The main focus of this proposal is Aim 3, where a three year, multi-center clinical trial en-
rolling one hundred and twenty (120) patients with metastatic or locally advanced and surgically unresectable
PDAC will be conducted at TJU and Bergen. All patients will undergo standard of care chemotherapy, with
one-half receiving adjunctive CEUS-IGDD. Patient outcomes will be compared by quantitative ultrasound as-
sessment, CT imaging including RECIST criteria, ECOG grade, and immunohistochemistry to assess local
progression-free and overall survival with the main endpoint being to increase the number of chemo-
therapy cycles by 75% in the IGDD group relative to controls.
摘要
胰腺癌是美国诊断出的第三种最常见的癌症,超过
2013年新增病例4.3万例。它是导致男性和女性癌症相关死亡的第四大原因。
尽管如此,胰腺导管腺癌的存活率并没有显著的改善。
诺玛(PDAC)患者在过去30多年。因此,有一个相当可观和紧迫的问题
临床需要制定有效的药物输送和治疗监测的创新战略,重新
为改善PDAC患者的预后而苦恼。我们的建议旨在开发对比度增强的
超声介导图像引导药物传递(CEUS-IGDD)将成为该方法学,并将其从
从实验室到诊所。具体任务旨在提高对控制的理解和方法
和监测这个IGDD平台,最初的临床重点是增强标准的有效性
化疗药物治疗不能手术的PDAC。
该项目本身就构成了一个多学科的挑战(技术、生物、物理和
医学),我们解决关键障碍的战略因此团结了一个跨学科的学术团队
以及来自通用电气全球研究公司(GE Global Research)、霍克兰大学医院和华盛顿大学的行业调查人员
卑尔根(一起:卑尔根)、托马斯·杰斐逊大学(TJU)和拉什大学医学中心
以色列理工学院和葛兰素史克(GSK)的努力更为有限。
目标1将开发工具和方法来确定最佳条件(声学状态、气泡类型)
最大限度地提供药物,最大限度地应用诊断范围内的声能。AIM 2利用两个COM-
补充建立小鼠胰腺癌模型,用人MIA-2luc(卑尔根)和
Panc-1(TJU)细胞株。CEUS-IGDD的疗效将使用生物分布数据和QUAU-IGDD进行评估。
监测治疗反应的定量成像方法预期中位生存期至少为5
与接受治疗的动物相比,治疗组的肿瘤体积减少了50%
一个人吸毒。这项建议的主要焦点是目标3,其中一个为期三年的多中心临床试验-
120例转移性或局部晚期且无法手术切除的患者
PDAC将在TJU和卑尔根进行。所有患者都将接受标准护理化疗,
一半接受辅助CEU-IGDD。患者的结果将通过定量超声进行比较,因为-
评估,CT成像包括RECIST标准,ECOG分级,和免疫组织化学评估局部
无进展和总存活率,主要终点是增加化疗的数量.
与对照组相比,IGDD组的治疗周期减少了75%。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Flemming Forsberg其他文献
Flemming Forsberg的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Flemming Forsberg', 18)}}的其他基金
Vevo 3100 ultrasound scanner and PV loop system
Vevo 3100 超声波扫描仪和 PV 环路系统
- 批准号:
10177118 - 财政年份:2021
- 资助金额:
$ 62.44万 - 项目类别:
Prostate Cancer Diagnosis by Multiparametric Ultrasound
多参数超声诊断前列腺癌
- 批准号:
10472567 - 财政年份:2020
- 资助金额:
$ 62.44万 - 项目类别:
Prostate Cancer Diagnosis by Multiparametric Ultrasound
多参数超声诊断前列腺癌
- 批准号:
10199974 - 财政年份:2020
- 资助金额:
$ 62.44万 - 项目类别:
Prostate Cancer Diagnosis by Multiparametric Ultrasound
多参数超声诊断前列腺癌
- 批准号:
10032625 - 财政年份:2020
- 资助金额:
$ 62.44万 - 项目类别:
Optimizing Ultrasound Enhanced Delivery of Therapeutics
优化超声增强治疗的输送
- 批准号:
10217039 - 财政年份:2016
- 资助金额:
$ 62.44万 - 项目类别:
Optimizing Ultrasound Enhanced Delivery of Therapeutics
优化超声增强治疗的输送
- 批准号:
9185490 - 财政年份:2016
- 资助金额:
$ 62.44万 - 项目类别:
Preventing Spinal Infection: Ultrasound Triggered Prophylaxis
预防脊柱感染:超声触发预防
- 批准号:
9233017 - 财政年份:2016
- 资助金额:
$ 62.44万 - 项目类别:
Preventing Spinal Infection: Ultrasound Triggered Prophylaxis
预防脊柱感染:超声触发预防
- 批准号:
9898313 - 财政年份:2016
- 资助金额:
$ 62.44万 - 项目类别:
Detection of High Grade Prostate Cancer with Subharmonic Ultrasound Imaging
用次谐波超声成像检测高级别前列腺癌
- 批准号:
9024279 - 财政年份:2016
- 资助金额:
$ 62.44万 - 项目类别:
Optimizing Ultrasound Enhanced Delivery of Therapeutics
优化超声增强治疗的输送
- 批准号:
10612329 - 财政年份:2016
- 资助金额:
$ 62.44万 - 项目类别:
相似海外基金
Nonlinear Acoustics for the conditioning monitoring of Aerospace structures (NACMAS)
用于航空航天结构调节监测的非线性声学 (NACMAS)
- 批准号:
10078324 - 财政年份:2023
- 资助金额:
$ 62.44万 - 项目类别:
BEIS-Funded Programmes
ORCC: Marine predator and prey response to climate change: Synthesis of Acoustics, Physiology, Prey, and Habitat In a Rapidly changing Environment (SAPPHIRE)
ORCC:海洋捕食者和猎物对气候变化的反应:快速变化环境中声学、生理学、猎物和栖息地的综合(蓝宝石)
- 批准号:
2308300 - 财政年份:2023
- 资助金额:
$ 62.44万 - 项目类别:
Continuing Grant
University of Salford (The) and KP Acoustics Group Limited KTP 22_23 R1
索尔福德大学 (The) 和 KP Acoustics Group Limited KTP 22_23 R1
- 批准号:
10033989 - 财政年份:2023
- 资助金额:
$ 62.44万 - 项目类别:
Knowledge Transfer Partnership
User-controllable and Physics-informed Neural Acoustics Fields for Multichannel Audio Rendering and Analysis in Mixed Reality Application
用于混合现实应用中多通道音频渲染和分析的用户可控且基于物理的神经声学场
- 批准号:
23K16913 - 财政年份:2023
- 资助金额:
$ 62.44万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Combined radiation acoustics and ultrasound imaging for real-time guidance in radiotherapy
结合辐射声学和超声成像,用于放射治疗的实时指导
- 批准号:
10582051 - 财政年份:2023
- 资助金额:
$ 62.44万 - 项目类别:
Comprehensive assessment of speech physiology and acoustics in Parkinson's disease progression
帕金森病进展中言语生理学和声学的综合评估
- 批准号:
10602958 - 财政年份:2023
- 资助金额:
$ 62.44万 - 项目类别:
The acoustics of climate change - long-term observations in the arctic oceans
气候变化的声学——北冰洋的长期观测
- 批准号:
2889921 - 财政年份:2023
- 资助金额:
$ 62.44万 - 项目类别:
Studentship
Collaborative Research: Estimating Articulatory Constriction Place and Timing from Speech Acoustics
合作研究:从语音声学估计发音收缩位置和时间
- 批准号:
2343847 - 财政年份:2023
- 资助金额:
$ 62.44万 - 项目类别:
Standard Grant
Flow Physics and Vortex-Induced Acoustics in Bio-Inspired Collective Locomotion
仿生集体运动中的流动物理学和涡激声学
- 批准号:
DGECR-2022-00019 - 财政年份:2022
- 资助金额:
$ 62.44万 - 项目类别:
Discovery Launch Supplement
Collaborative Research: Estimating Articulatory Constriction Place and Timing from Speech Acoustics
合作研究:从语音声学估计发音收缩位置和时间
- 批准号:
2141275 - 财政年份:2022
- 资助金额:
$ 62.44万 - 项目类别:
Standard Grant